BMC Anesthesiology

Open Access

CrossMark

Lidocaine relaxation in isolated rat aortic rings is enhanced by endothelial removal: possible role of K_v, K_{ATP} channels and A_{2a} receptor crosstalk

Aryadi Arsyad[1,2] and Geoffrey P. Dobson[1*]

Abstract

Background: Lidocaine is an approved local anesthetic and Class 1B antiarrhythmic with a number of ancillary properties. Our aim was to investigate lidocaine's vasoreactivity properties in intact versus denuded rat thoracic aortic rings, and the effect of inhibitors of nitric oxide (NO), prostenoids, voltage-dependent K_v and K_{ATP} channels, membrane Na^+/K^+ pump, and A_{2a} and A_{2b} receptors.

Methods: Aortic rings were harvested from adult male Sprague Dawley rats and equilibrated in an organ bath containing oxygenated, modified Krebs-Henseleit solution, pH 7.4, 37 °C. The rings were pre-contracted sub-maximally with 0.3 μM norepinephrine (NE), and the effect of increasing lidocaine concentrations was examined. Rings were tested for viability after each experiment with maximally dilating 100 μM papaverine. The drugs 4-aminopyridine (4-AP), glibenclamide, 5-hydroxydecanoate, ouabain, 8-(3-chlorostyryl) caffeine and PSB-0788 were examined.

Results: All drugs tested had no significant effect on basal tension. Lidocaine relaxation in intact rings was biphasic between 1 and 10 μM (Phase 1) and 10 and 1000 μM (Phase 2). Mechanical removal of the endothelium resulted in further relaxation, and at lower concentrations ring sensitivity (% relaxation per μM lidocaine) significantly increased 3.5 times compared to intact rings. The relaxing factor(s) responsible for enhancing ring relaxation did not appear to be NO- or prostacyclin-dependent, as L-NAME and indomethacin had little or no effect on intact ring relaxation. In denuded rings, lidocaine relaxation was completely abolished by K_v channel inhibition and significantly reduced by antagonists of the MitoK_{ATP} channel, and to a lesser extent the SarcK_{ATP} channel. Curiously, A_{2a} subtype receptor antagonism significantly inhibited lidocaine relaxation above 100 μM, but not the A_{2b} receptor.

Conclusions: We show that lidocaine relaxation in rat thoracic aorta was biphasic and significantly enhanced by endothelial removal, which did not appear to be NO or prostacyclin dependent. The unknown factor(s) responsible for enhanced relaxation was significantly reduced by K_v inhibition, 5-HD inhibition, and A_{2a} subtype inhibition indicating a potential role for crosstalk in lidocaine's vasoreactivity.

Keywords: Rat aorta, Lidocaine, Relaxation, Vasodilation, Endothelium, Nitric oxide, Redox stress

* Correspondence: geoffrey.dobson@jcu.edu.au
[1]Heart, Trauma and Sepsis Research Laboratory, Australian Institute of Tropical Health and Medicine, College of Medicine and Dentistry, James Cook University, 1 James Cook Drive, 4811 Queensland, Australia
Full list of author information is available at the end of the article

Background

Lidocaine is a local amide-type cationic anesthetic, which acts by blocking voltage-dependent Na^+ fast channels in excitable cells (EC50, 50–100 uM) [1]. At lower concentrations, lidocaine is an approved Class 1B antiarrhythmic [2] and exerts anti-inflammatory [3], neuroprotective [4], energy-lowering [5], anti-ischemic [6, 7], anti-oxidant [8, 9] and platelet-neutrophil interactive [10, 11] properties.

Lidocaine has also been shown to exert a number of vasomodulatory properties in isolated vessels including: 1) endothelium-independent relaxation [12, 13], and 2) vascular smooth muscle relaxation [12, 14, 15] or contraction [15–19] properties. The apparent paradoxical nature of lidocaine on vascular smooth muscle is often explained as being dose-dependent with vasoconstriction of peripheral blood vessels occurring at low concentrations of lidocaine (~5 uM) and vasodilation at higher levels (>50 uM) [14, 16, 20, 21]. In the rat carotid artery, Kinoshita further proposed that lidocaine may impair the vasodilator response via the activation of ATP-sensitive K^+ channels which may exacerbated by hypoxia [19]. Earlier the same group showed that in pre-contracted denuded rat aortic rings that acidification promoted lidocaine relaxation and alkanization led to vasoconstriction [18].

These confounding effects of lidocaine vasoreactivity appear to be linked to differential modulation of multiple channels including Na^+ channels [2], inwardly-rectifying K^+ channels [22], Ca^{2+} channels [13, 23] and/or K_{ATP} channels [18, 19]. Vasodilation may involve nitric oxide (NO) [24–26], redox regulation [9] and possible convergence of a multitude of downstream cAMP and cGMP signalling cascades that lead to changes in cytosolic Ca^{2+} [27]. Hollmann and colleagues, for example, identified lidocaine and G-protein coupled receptor systems as potential intracellular signalling mechanisms, and the Gq protein subunit as a possible common target [28]. In 2003, Benkwitz et al., also showed that the G_i protein subunit was enhanced by lidocaine, and that it was potentiated adenosine A1-receptor signalling [29]. The group proposed that lidocaine was not an A1-receptor agonist but enhanced adenosine-A1 receptor signalling separate from its local anesthetic Na^+ channel properties [29]. The aim of the present study was to investigate the nature of lidocaine relaxation in isolated rat thoracic aortic rings, and examine the effect of inhibitors of NO, prostenoids, K_v channels, K_{ATP} channels, and adenosine A_{2a} and A_{2b} receptors. Adenosine A_2 receptors were chosen because they are widely known to modify vascular tone [30], and may therefore be involved in possible crosstalk in lidocaine relaxation [29].

Methods

Animals

Male Sprague Dawley rats (300–350 g, $n = 72$) were fed ad libitum and housed in a 12-h light/dark cycle. On the day of the experiment rats were anaesthetised with Na-thiopentone (100 mg/kg). Animals were treated in accordance with the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996). The James Cook University ethics approval number for the studies was A1535. Lidocaine hydrochloride was sourced as a 2% solution (Ilium) from the local Pharmaceutical Suppliers (Lyppard, Queensland). All other chemicals, drugs and inhibitors were purchased from Sigma Aldrich (Castle Hill, NSW).

Aortic ring preparation and organ bath tension measurements

The thoracic cavity of anesthetized rats was opened and the thoracic aorta was harvested and placed in a modified ice-cold solution of Krebs Henseleit (118 mM NaCl, 4.7 mM KCl, 1.2 mM Na_2PO_4, 0.5 mM $MgCl_2$, 1.12 mM $CaCl_2$, 25 mM $NaHCO_3$, 0.03 mM EDTA) pH 7.4 with 11 mM glucose. The aorta was carefully dissected from surrounding fat and connective tissue and cut into short transverse segments. Intact aortic rings were isolated from each rat and used without further processing. In those studies that required removal of the endothelium, intact rings were denuded by gently rubbing the intimal surface of the vessel segment with a smooth metal probe. Successful removal of the endothelium was assessed by testing the aortic ring for a vasodilatory response to 10 μM acetylcholine (final concentration).

After preparation, intact or denuded aortic rings (3 to 4 mm long) were equilibrated in a standard 10 ml volume organ bath (Radnotti Glass, ADinstruments, NSW, AUS) containing modified Krebs Henseleit (see above) and continuously bubbled with 95% O_2 and 5% CO_2 at 37 °C for 15 min (zero tension) (Fig. 1). The rings were vertically mounted on small stainless steel triangles, stirrups and connected to an isometric force transducer (PANLAB, distributed by ADInstruments as MLT 0201/RAD, NSW, AUS) coupled to a computer based data acquisition system (PowerLab, ADInstruments) and data recording software LabChart 7 (ADInstruments Pty Ltd., Castle Hill, Australia) (Fig. 1).

The ring tension was manually adjusted to 1.5 g and equilibrated for 60 min. A tension of 1.5 g was chosen from the literature for thoracic aortic rings prepared from 300 to 400 g rats [18, 31] and preliminary studies verified this tension. During equilibration, the solution was changed in 15 min intervals. The aortic rings were then washed with freshly prepared Krebs Henseleit buffer pH 7.4 and the tension was readjusted to 1.5 g

Fig. 1 A graphical scheme of the rat thoracic aorta ring apparatus for isometric force measurements, receptor sensitivity and smooth muscle-endothelial interactions. See Methods for details

tension. Each preparation was sub-maximally contracted using 3 µl of 0.1 mM NE (0.3 µM final concentration) [15, 32]. Those aortic rings that failed to contract were discarded. Ten microliters of 10 mM acetylcholine (10 µM final concentration) was applied to confirm the presence or absence of an intact endothelium in all preparations. Acetylcholine will induce rapid relaxation of precontracted rings if the endothelium is intact and if the endothelium is removed (or denuded) the rings will remain in contracted state [33]. Aortic rings were considered intact if the relaxation induced by 10 µM ACh was greater than 80%, and the aortic ring was assumed denuded if relaxation was less than 10%.

Rings were contracted at least two more times before each experiment until a reproducible contractile response was obtained. Ten to 15 min after this state was achieved the experiment was commenced because preliminary studies showed that the increase in tension and plateau from 0.3 µM of NE was reached at 10 min and remained at this plateau level for over 60 min, the time course of each experiment.

Lidocaine relaxation in intact and denuded rat aortic rings: a scheme of the experimental protocol

Lidocaine-HCl was added into the oxygenated organ bath containing KH solution to obtain 1, 5, 10, 50, 100, 500 and 1000 µM lidocaine concentrations. The change

in tension of pre-contracted intact or denuded rings was measured. Responsiveness was defined as % relaxation per µM lidocaine. The inhibitors used in this study were incubated in organ bath 20–30 min before NE was administered followed by lidocaine incremental administration. These included 1). 100 µM N^G-nitro-L-arginine Methyl Ester (L-NAME) (nitric oxide synthetase inhibitor) and 10 µM indomethacin (cyclooxygenase or prostaglandin inhibitor e.g. prostacyclin). NO and prostacyclin are two major endothelial derived relaxation factors (EDRF), and the inhibitors were only applied in endothelium intact aortic rings. 2). 1 mM 4-aminopyridine (4-AP) (Non-selective voltage-dependent K^+-channel blocker of the Kv1 to Kv4 families rather than Kv7 channels) [34–36], 10 µM glibenclamide (Non-selective SarcK$_{ATP}$ channel blocker) [37, 38] and 1 mM 5-hydroxydecanoate (5-HD) (Non-selective MitoK$_{ATP}$ channel blocker) [39], and Na$^+$/K$^+$-ATPase inhibitor (100 µM ouabain) [40]. While 5-HD is commonly used in the literature as a specific MitoK$_{ATP}$ channel blocker [41], Hanley and colleagues have shown that 5-HD is not a selective inhibitor of mitochondrial K$_{ATP}$ channels but can act a substrate for the mitochondrial outer membrane enzyme acyl-CoA synthetase in the beta-oxidation pathway [42]), and it is also capable of playing a role as an inhibitor of sarcolemmal K$_{ATP}$ channels in the presence of ATP (which was not the case in our

study) [43]. These inhibitors were applied to intact endothelium rings in the presence of L-NAME and indomethacin, and without the presence of L-NAME and indomethacin in denuded aortic rings, and 3) The adenosine A_{2a} receptor inhibitor, 100 μM 8-(3-chlorostyryl) caffeine (CSC) [44–46], and the A_{2b} receptor inhibitor, 10 μM 8-(4-(4-(4-chlorobenzyl)piperazine-1-sulfonyl)-phenyl)-1-propylxanthine (PSB-0788) [47]. These high affinity antagonists have been used in rodent studies with reported K_i values of 24 nM for CSC [48] and 0.393 nM for PSB-0788 [47]. CSC has also been shown to be 520-fold selective for A2a-adenosine receptors in radioligand binding assays in the rat brain (K_i, 54 nM) with little or no effect on A1 receptors [44]. The inhibitors were applied to isolated rat aortic rings in an oxygenated medium. At the end of each experiment, the rings were tested for viability (or patency) by being maximally dilated with 100 μM papaverine, and relaxation was expressed as percentage of maximal relaxation to papaverine [40, 49].

Statistics
Values are expressed as mean ± SEM. The number of rats was selected from a priori G-power analysis to achieve a level of 1.0. Values are expressed as mean ± SEM. All data was tested for normality using *Kolmogorov-Smirnov* test. Relaxation responses to lidocaine were analysed for homogeneity of variances followed by two-way ANOVA coupled with the *Bonferroni* post-hoc test for individual data point comparisons. The alpha level of significance for all experiments was set at $p < 0.05$.

Results
Effect of increasing lidocaine on relaxation in intact and denuded rings
Intact rings
The gram tension produced with NE administration in endothelium intact rings was not significantly different from denuded aortic rings. Lidocaine produced a concentration-dependent, biphasic relaxation relationship in intact and denuded rat aortic rings (Fig. 2). The percentage relaxation in intact rat aortic rings was 1.3, 6.0, 8.6 and 41.7% at 1, 10, 100 and 1000 uM lidocaine respectively. The first relaxation phase was between 1 and 10 uM (Phase 1) and the second phase was from 10 to 1000 uM lidocaine (Phase 2) (log concentration scale) (Fig. 2). The percentage relaxation per μM lidocaine (ring responsiveness) was 0.47% from 1 to 10 μM, 0.029% between 10 and 100 μM and 0.037% increase per μM between 100 and 1000 μM lidocaine. The maximum relaxation from 1 to 1000 μM lidocaine in intact rings was 40.4%.

Fig. 2 Concentration response curves to lidocaine in intact and denuded isolated rat aortic rings. Relaxation is expressed as percent of maximal relaxation to 100 μM papaverine. Points represent mean ± S.E.M of aortic rings. *$P < 0.05$ statistical difference in responses between the intact and denuded rings. Lidocaine concentrations are on a log scale. Total animals $n = 12$

Denuded rings
Removal of the endothelium significantly increased Phase 1 relaxation responsiveness from 0.47 to 1.80% per μM lidocaine between 1 and 10 μM (Fig. 2). Interestingly, above 10 μM removing the endothelium had little or no significant effect on ring responsiveness to increasing lidocaine compared to intact rings. From 10 to 100 μM, % relaxation per μM was 0.033% and from 100 to 1000 μM was 0.028% (Fig. 2). However, despite this similar responsiveness, at each lidocaine concentration up to 100 μM, the absolute percentage relaxation was significantly higher in denuded rings than intact rings. The absolute % relaxation in denuded rings was 5.5, 14, 22, 24, 25, 36 and 50% at 1, 5, 10, 50, 100, 500 and 1000 uM lidocaine respectively (Fig. 2). Thus the effect of removing the endothelium was to significantly enhance ring *sensitivity* or *responsiveness* at lower lidocaine concentrations (1 to 10 μM) but not in the higher range (10 to 1000 μM), even though absolute relaxation values were significantly higher at each lidocaine concentration (1 to 1000 μM) in denuded versus intact rings (Fig. 2).

Effect of L-NAME and indomethacin in intact aortic rings
In intact aortic rings, pre-treatment with L-NAME and indomethacin did not significantly change lidocaine relaxation from 1 to 1000 μM, although there was a trend towards inhibition at higher concentrations (Fig. 3). Between 1 and 10 μM, the change in relaxation was 0.44% per μM, 0002% per μM between 10 and 100 μM and 0.029% per μM from 100 to 1000 μM. At 500 μM lidocaine, the % relaxation was 17% (32% lower than intact rings) and at

Fig. 3 Concentration-response curves to lidocaine with and without the presence of L-NAME + indomethacin in intact isolated rat aortic rings. Relaxation is expressed as percent of maximal relaxation to 100 μM papaverine. Points represent mean ± S.E.M of aortic rings. *$P < 0.05$ statistically different in the presence of L-NAME + indomethacin compared to control on intact rings. Lidocaine concentrations are on a log scale. Total animals $n = 12$

1000 μM lidocaine was 32% (24% lower than intact rings), but the differences were not significant (Fig. 3).

Effect of K_v, SarcK$_{ATP}$, MitoK$_{ATP}$ and Na$^+$/K$^+$ ATPase antagonists on relaxation in intact and denuded rings

The effects of voltage-dependent K_v, SarcK$_{ATP}$, mitoK$_{ATP}$ and Na$^+$/K$^+$-ATPase antagonists on lidocaine relaxation in intact rat aortic rings are shown in Fig. 4. After pre-contracted with NE, ring basal tensions were 3.3 ± 0.09 g; 3.5 ± 0.17 g; 3.4 ± 0.09 g; 3.4 ± 0.14 g ($n = 8$ each) for 4-AP, glibenclamide, 5-HD and ouabain groups, respectively; and not significantly different from NE with L-NAME and indomethacin controls (3.2 ± 0.19 g, $n = 8$). In endothelial intact aortic rings, exposure of rings to these antagonists did not alter lidocaine-induced relaxation compared to controls (Fig. 4).

In denuded rings, the effect of 1 mM 4-AP was to totally abolish relaxation up to 500 μM after which relaxation was 12 ± 5% ($n = 8$) compared to 39 ± 5% in denuded controls (i.e. 4-AP led to a 70% decrease in relaxtion) (Fig. 5a). 4-AP inhibition was significant from 1 to 1000 μM lidocaine ($p < 0.0001$). The effect of glibenclamide (10 μM) had little or no effect on relaxation up to 10 μM lidocaine compared to de-nuded controls (Fig. 5b) and was ~20% lower at higher lidocaine concentrations; however, the differences were not significant. Exposure of denuded rings to 1 mM 5-HD led to ~50% decrease in lidocaine re-laxation at 5 to 1000 μM lidocaine which was signifi-cant >50 μM (Fig. 5c). The presence of 100 μM ouabain, a Na$^+$/K$^+$-ATPase channel inhibitor, had little or no significant effect on lidocaine-induced relax-ation (Fig. 5d).

Effect of A_{2a} and A_{2b} antagonists in intact and denuded rat aortic rings

The basal tension of NE-precontracted CSC group was 3.1 ± 0.16 g and PSB-0788 groups 3.7 ± 0.07 g ($n = 8$ each) and not significantly different from controls (3.2 ± 0.19 g, $n = 8$). Adenosine A_{2a} antagonist 8-(3-chlorostyryl) caf-feine (CSC) significantly decreased lidocaine relaxation in the intact rat aorta at 100 to 1000 μM (Fig. 6). Divergence began to occur at 50 μM lidocaine with relaxation values of 2, −2.8, −3.4 and 7.6% at 50, 100, 500 and 1000 μM lidocaine respectively. In direct contrast, the incubation with PSB-0788, an adenosine A_{2b} antagonist, did not mod-ify lidocaine-induced relaxation curve at any concentra-tion used in NE pre-contracted aortic rings (Fig. 6).

In denuded rings, the basal tension of aortic rings with the presence of CSC (2.5 ± 0.15 g) or PSB-0788 (3.1 ± 0.18 g) was not significantly different. CSC had no effect on relaxation up to 10 uM lidocaine then strongly inhib-ited relaxation up to 500 μM (Fig. 6). The maximum lido-caine relaxation was 13 ± 6%, which was significantly lower than control denuded rings (39 ± 5%, $p < 0.0001$) (Fig. 6). The adenosine A_{2b} receptor blocker PSB-0788 (10 μM) also decreased lidocaine relaxation by up to 50% but this effect was not significant (Fig. 6). At 10, 100, and 1000 μM lidocaine, the relaxation percentages were 7 ± 1, 10 ± 2, and 31 ± 3%, respectively compared to 16 ± 3, 19 ± 4, and 39 ± 5% in denuded controls (Fig. 6).

Discussion

Despite decades of investigation, the mechanisms of lidocaine relaxation in the rat thoracic aorta, and muscu-lar resistance arterioles are not fully understood [12, 14–16, 20, 21]. We report in isolated rat thoracic rings, pre-contracted with NE, that lidocaine relaxation was: 1) bi-phasic from 1 to 10 μM and 10 to 1000 μM, 2) signifi-cantly enhanced by endothelial removal, particularly from 1 to 100 μM, 3) not significantly affected in the presence of L-NAME- and indomethacin in intact rings, 4) abolished by 4-AP in denuded rings and significantly reduced by 5-HD, and to a lesser extent glibenclamide, and 5) significantly reduced by A_{2a} subtype antagonist from 100 to 1000 μM, but not A_{2b}. We discuss the pos-sible physiological significance of the biphasic nature of lidocaine relaxation, enhancement after endothelial re-moval, and potential role for crosstalk with the A_{2a} sub-type and voltage-dependent K_v and K_{ATP} channels.

Lidocaine relaxation was biphasic and endothelial dependent

We found in oxygenated, glucose-containing Krebs Henseleit buffer, pH 7.4 at 37 °C: 1) little or no change in relaxation in rat aortic rings at low lidocaine concentra-tions, and 2) a strong endothelial dependence which en-hanced relaxation after its removal (Fig. 2). The data

Fig. 4 Concentration-response curves to lidocaine with and without the presence of specific ion channel blockers in intact isolated rat aortic rings. **a** In the presence of 1 mM 4-aminopyridine. **b** In the presence of 1 mM 5-Hydroxydecanoate. **c** In the presence of 10 μM glibenclamide. **d** In the presence of 100 μM ouabain. Relaxation is expressed as percent of maximal relaxation to 100 μM papaverine. Points represent mean ± S.E.M of aortic rings in the presence of L-NAME and indomethacin. *$P < 0.05$ statistical difference in responses between the presence and the absence of inhibitors on intact rings. Lidocaine concentrations are on a log scale. Total animals $n = 16$

suggest that the presence of an intact endothelium acted like a "brake" to reduce lidocaine relaxation, and upon its removal activated some putative factor to enhance relaxation. Our findings are in contrast with those reported in rat cremaster skeletal muscle [14], epicardial porcine coronary arteries [50], human radial arterial rings [51], human mammary arteries [52], and rabbit carotid arteries [15, 53], where lidocaine at low levels potentiated vasoconstriction, and at high concentrations led to relaxation. Jembeck and Samuelson further reported in isolated rings from radial arteries that lidocaine led to significantly stronger contractions after the endothelium was mechanically removed [51]. Reasons for the differences are not clear at present but may relate to species, age, mode of

sacrifice, physiological state, pre-contractile conditions activating different channels and receptors (e.g. alteration of the membrane smooth muscle potential with high K$^+$ versus NE or phenylephrine to pre-contract isolated rings), tissue preparation, different endothelial removal procedures and possible damage, buffer conditions, temperature, P$_{O2}$ availability, and the sequence of drug additions and concentrations. Another important difference is vessel type; we studied the rat thoracic aorta, which is a large, highly elastic artery that normally offers little resistance to flow but assists in coupling the heart, as a pump and pressure-generator, to the arterial system by changing aortic compliance not resistance [54].

Fig. 5 Concentration-response curves to lidocaine with and without the presence of specific ion channel blockers in denuded isolated rat aortic rings. **a** In the presence of 1 mM 4-aminopyridine. **b** In the presence of 1 mM 5-Hydroxydecanoate. **c** In the presence of 10 μM glibenclamide. **d** In the presence of 100 μM ouabain. Relaxation is expressed as percent of maximal relaxation to 100 μM papaverine. Points represent mean ± S.E.M of aortic rings in the presence of L-NAME and indomethacin. *$P < 0.05$ statistical difference in responses between the presence and the absence of inhibitors on intact rings. Lidocaine concentrations are on a log scale. Total animals $n = 16$

That lidocaine relaxation occurred from 1 to 1000 uM is consistent with the study of Shan and colleagues who showed that lidocaine relaxed phenylephrine or KCl (60 mM) precontracted rat aortic rings in a concentration-dependent manner [13]. However, their study differed from ours because they showed lidocaine relaxation was not significantly modified by endothelium removal, and their aortic rings were obtained from rats sacrificed by stunning and cervical dislocation, not anesthesia [13]. Our study also agreed with Turan and colleagues who showed lidocaine relaxed phenylephrine-precontracted rabbit thoracic aorta intact and denuded rings, however, when lidocaine (1 to 100 μM) was applied 15 min before the addition of phenylephrine it produced contractions at high concentrations (up to 10 mM), and endothelium removal did not significantly affect contractile activity. This example demonstrates the dynamics of the pre-contractile state and the importance of specifying the sequence of drug administration,

which can produce different results. Further studies are required to investigate these discrepancies in the thoracic aorta of rat and other species prepared from different modes of sacrifice, different precontracted states and basal tone.

Lidocaine relaxation enhancement involves an endothelium-smooth muscle coupling and possible activation of K_v and K_{ATP} channels

Since lidocaine relaxation displayed a strong endothelial-dependence (Fig. 2), it suggested a possible role for NO release or activation of the cyclo-oxygenase pathway and/or their interactions with the adrenoreceptors on vascular smooth muscle. Surprisingly, we found little or no effect of either L-NAME and indomethacin on lidocaine relaxation (Fig. 3) indicating that the putative relaxing factor after endothelial removal was neither NO nor prostacyclin. Other unknown factor(s) must be

INTACT RAT AORTIC RINGS

DENUDED RAT AORTIC RINGS

Fig. 6 Concentration-response curves to lidocaine with and without the presence of adenosine A_{2ab} receptor blockers in intact and denuded isolated rat aortic rings. **a** (Adenosine A2a receptor antagonist) In the presence of 100 μM 8-(3-Chlorostyryl) caffeine. **b** (Adenosine A2b receptor antagonist) In the presence of 10 μM PSB-0788. Relaxation is expressed as percent of maximal relaxation to 100 μM papaverine. Points represent mean ± S.E.M of aortic rings in the presence of L-NAME and indomethacin. *$P < 0.05$ statistical difference in responses between the presence and the absence of inhibitors on intact rings. Lidocaine concentrations are on a log scale. Total animals $n = 16$

released upon endothelial removal to enhance lidocaine relaxation. Another possibility is endothelial-dependent activation of smooth muscle voltage-dependent Kv channels and/or smooth muscle mitochondrial K_{ATP} channels, since we showed that 4-AP completely abolished relaxation (Figs. 3a and 4a) and 5-HD led to ~50% inhibition in denuded rings (Figs. 4c and 5c).

Enhanced lidocaine relaxation may also have come from changing the cellular redox state and reactive oxygen species (ROS) derived from NAD(P)H oxidases [55, 56], as it has been reported that lidocaine at higher concentrations protects against ROS attack in rabbit abdominal aorta [9]. Rogers and colleagues further showed that 4-AP-sensitive K_v channels are redox sensitive and contribute to H_2O_2-induced coronary vasodilation [57]. In summary, we conclude that enhanced lidocaine relaxation after endothelial

removal does not appear to involve the direct activation of NO or prostanoid-linked pathways, and that other relaxing factors and downstream signalling pathways, possibly involving Kv and/or 5-HD sensitive K_{ATP} channels, are involved.

Smooth muscle adenosine A_{2a} modulation may also be involved in the enhanced lidocaine relaxation

The present study also suggests an intriguing possibility for enhancing lidocaine relaxation may be activation of the A_{2a} receptor on vascular smooth muscle. A surprising result was that lidocaine relaxation above 50 μM in intact and denuded rat aortic rings was significantly inhibited by 75 to 100% in the presence of A_{2a} blocker 8-(3-chlorostyryl) caffeine (CSC) (Fig. 5). This implies that the A_{2a} receptor may be involved in the presence or

absence of an intact endothelium. Assuming CSC has high specificity for A_{2a} receptors [44], this antagonist may reduce lidocaine relaxation from one or more of the following mechanisms: 1) Directly or indirectly increasing Ca^{2+} influx from extracellular sources such as L-type Ca^{2+} channels [58], 2) increasing the release of Ca^{2+} from intracellular stores (e.g. sarcoplasmic or endoplasmic) to increase cytosolic free Ca^{2+}, and/or 3) increasing myofibrillar contractile sensitivity to existing free Ca^{2+} (signalled via the RhoA/Rho kinase pathway), increase cross-bridge cycling and development of force [55, 59]. Possible crosstalk between A_{2a} receptors and lidocaine may also involve transmembrane domains of adenyl cyclase and other downstream signalling pathways to alter intracellular free Ca^{2+} and/or myofibrillar sensitisation.

To our knowledge, little or no data exist on adenosine and lidocaine interactions in intact rat aortic rings or endothelial-vascular smooth muscle interactions. Adenosine A_{2a} and A_{2b} receptors are present on vascular endothelium and smooth muscle of many vessels [60, 61] and when activated can lead to vasodilation. A_{2a} receptor vasodilation is thought to involve: 1) endothelial NO production which activates smooth muscle guanylyl cyclase via opening Kir channels [61], and/or 2) more direct smooth muscle A_{2a} receptor activation which in turn stimulates mostly Gs proteins (and Gq) and cAMP signalling pathways to reduce intracellular Ca^{2+} levels [61, 62]. In addition, adenosine A_{2a} activation may activate sarcolemma Ca^{2+} channels and regulate influx in large elastic arteries and resistance vessels. Stella and colleagues showed that activation of A_2 receptors stimulates protein kinase A to inhibit L-type Ca^{2+} channels in rod photoreceptors resulting in a decreased Ca^{2+} influx [63]. Gubitz and colleagues have proposed dual A_{2a} signalling involving the activation of both N- and P-type calcium channels by different G proteins and protein kinases in the some nerve terminals [64]. Gonvalves and colleagues showed that adenosine A_{2a} receptors facilitated Ca^{2+} uptake through class A calcium channels in rat hippocampal CA3 region [65].

Interestingly, Benkwitz and colleagues also showed that higher concentrations of lidocaine (1000 uM) in hamster oocytes potentiated $Galpha_i$-coupled A_1 receptor signalling by reducing cyclic AMP production in a dose-dependent manner through an unidentified mechanism [29]. The authors proposed that lidocaine was not an A1-receptor agonist *but enhanced adenosine-A1 receptor signalling*. They argued that lidocaine interacted with a pool of already activated $G\alpha i$ present in the cytoplasm and thereby facilitated its ability to inhibit adenylate cyclase leading to lower cAMP [29]. We did not examine adenosine A1 receptor antagonism We conclude from our study that A_{2a} receptor may have enhanced lidocaine relaxation activation by directly effecting vascular smooth muscle (Fig. 6), and this may have occurred by reducing

intracellular Ca^{2+} and/or myofibrillar contractile sensitization in intact isolated rat aortic rings, although the underlying mechanisms remain to be identified. Further studies are required to investigate the role of adenosine and lidocaine on membrane Ca^{2+} channel modulation in isolated rat aortic rings.

Limitations of the study and possible physiological significance

The present study examined lidocaine relaxation in isolated rat thoracic rings using length-tension experiments and a number of antagonists of NO, prostanoids, K_v, K_{ATP} and A_2 receptors under normoxic and normal pH conditions from healthy rats. Before definitive conclusions can be drawn regarding the nature of unknown relaxation factor(s), it would be important to examine separately and in combination other drug antagonists and agonists of NO, prostanoids, K_v, Sarc- and Mito-K_{ATP} channels and A_2 receptors on lidocaine relaxation in intact and denuded rings. Furthermore, to gain greater mechanistic insight into the nature of voltage-dependent K^+ channels and lidocaine vasorelaxation electrophysiological experiments would be essential. Leukotrienes, and leukotriene synthase inhibitors, may also be of interest because they have been shown to modulate rat aortic ring relaxation [66]. Possible physiological significance of the present study relates to lidocaine's effect to regulate in vivo compliance such as ventricular-arterial coupling functions linking the heart as a pump to tissue perfusion [67, 68]. However, further in vivo studies are required to test this hypothesis. Also our work may have clinical applicability on the ancillary properties of lidocaine at the site of injection during infiltration, nerve block, or epidural anesthesia [14], and on damaged endothelium such as in plaque formation, arterial and venous conduit protection for cardiopulmonary bypass grafting [69], prevention of vascular spasm during neurosurgery [70], lowering elevated intracranial pressure [71], lidocaine cardioplegia [72, 73], and other surgical applications [54].

Conclusions
We showed in isolated, oxygenated NE precontracted rat aortic rings that lidocaine relaxation was biphasic from 1 to 10 uM and 10 to 1000 uM. We further showed that lidocaine relaxation was significantly enhanced by endothelial removal, which did not appear to be NO or prostacyclin dependent. The putative unknown factor(s) responsible for enhanced relaxation may involve activation of smooth muscle voltage-sensitive K_v and 5-HD sensitive channels or pathways, and possible crosstalk with A_{2a} subtype receptor at higher lidocaine concentrations.

Author details
[1]Heart, Trauma and Sepsis Research Laboratory, Australian Institute of Tropical Health and Medicine, College of Medicine and Dentistry, James Cook University, 1 James Cook Drive, 4811 Queensland, Australia. [2]Physiology Department, Medical Faculty, Hasanuddin University, Jl. Perintis Kemerdekaan, Km. 10, 90213 Tamalanrea, Makassar, Indonesia.

References
1. Opie LH, Gersh BJ. Drugs for the heart. 7th ed. London: W.B. Saunders; 2008.
2. Wyman MG, Wyman RM, Cannom DS, Criley JM. Prevention of primary ventricular fibrillation in acute myocardial infarction with prophylactic lidocaine. Am J Cardiol. 2004;94(5):545–51.
3. Hollmann MW, Strumper D, Durieux ME. The poor man's epidural: systemic local anesthetics for improving postoperative outcomes. Med Hypotheses. 2004;63(3):386–9.
4. Butterworth J, Hammon JW. Lidocaine for neuroprotection: more evidence of efficacy. Anesth Analg. 2002;95(5):1131–3.
5. Seyfried FJ, Adachi N, Arai T. Suppression of energy requirement by lidocaine in the ischemic mouse brain. J Neurosurg Anesthesiol. 2005;17(2):75–81.
6. Cassuto J, Sinclair R, Bonderovic M. Anti-inflammatory properties of local anesthetics and their present and potential clinical implications. Acta Anaesthesiol Scand. 2006;50(3):265–82.
7. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res. 2004;61(3):481–97.
8. Tomoda MK, Tsuchiya M, Ueda W, Hirakawa M, Utsumi K. Lidocaine inhibits stimulation-coupled responses of neutrophils and protein kinase C activity. Physiol Chem Phys Med NMR. 1990;22(4):199–210.
9. Lee JM, Suh JK, Jeong JS, Cho SY, Kim DW. Antioxidant effect of lidocaine and procaine on reactive oxygen species-induced endothelial dysfunction in the rabbit abdominal aorta. Korean J Anesthesiol. 2010;59(2):104–10.
10. Schmidt W, Schmidt H, Bauer H, Gebhard MM, Martin E. Influence of lidocaine on endotoxin-induced leukocyte-endothelial cell adhesion and macromolecular leakage in vivo. Anesthesiology. 1997;87(3):617–24.
11. Huang GS, Lin TC, Wang JY, Ku CH, Ho ST, Li CY. Lidocaine priming reduces ADP-induced P-selectin expression and platelet-leukocyte aggregation. Acta Anaesthesiol Taiwan. 2009;47(2):56–61.
12. Turan NN, Demiryürek AT, Celebi H. Effects of lidocaine on rabbit isolated thoracic aorta. Pharmacol Res. 2000;42(5):453–8.
13. Shan QX, Lin DS, Jin HF, Gao Q, Lu Y, Xia Q. Endothelium-independent vasorelaxant effect of lidocaine in rat aortic rings. Conf Proc IEEE Eng Med Biol Soc. 2004;5:3753–6.
14. Johns RA, DiFazio CA, Longnecker DE. Lidocaine constricts or dilates rat arterioles in a dose-dependent manner. Anesthesiology. 1985;62(2):141–4.
15. Evans GR, Gherardini G, Gurlek A, Langstein H, Joly GA, Cromeens DM, Sukumaran AV, Williams J, Kilbourn RG, Wang B, et al. Drug-induced vasodilation in an in vitro and in vivo study: the effects of nicardipine, papaverine, and lidocaine on the rabbit carotid artery. Plast Reconstr Surg. 1997;100(6):1475–81.
16. Perlmutter N, Wilson R, Joyce M, Angello D, Gee D. Effect of lignocaine on coronary blood flow, systolic myocardial function and myocardial high energy phosphate stores in swine. Clin Exp Pharmacol Physiol. 1990;17(10): 697–706.
17. Gherardini G, Gürlek A, Cromeens D, Joly GA, Wang BG, Evans GR. Drug-induced vasodilation: in vitro and in vivo study on the effects of lidocaine and papaverine on rabbit carotid artery. Microsurgery. 1998;18(2):90–6.
18. Kinoshita H, Iranami H, Kimoto Y, Dojo M, Hatano Y. Mild alkalinization and acidification differentially modify the effects of lidocaine or mexiletine on vasorelaxation mediated by ATP-sensitive K+ channels. Anesthesiology. 2001;95(1):200–6.
19. Kinoshita H, Kimoto Y, Nakahata K, Iranami H, Dojo M, Hatano Y. The role of K+ channels in vasorelaxation induced by hypoxia and the modulator effects of lidocaine in the rat carotid artery. Anesth Analg. 2003;97(2):333–8.
20. Abe S, Maguro T, Endoh N, Terashima M, Mitsuoka M, Akatsu M, Kikuchi Y, Takizawa K. Response of the radial artery to three vasodilatory agents. Catheter Cardiovasc Interv. 2000;49:253–6.
21. Satoh K, Kamada S, Kumagai M, Sato M, Kuji A, Joh S. Effect of lidocaine on swine lingual and pulmonary arteries. J Anesth. 2015;29(4):529–34.
22. Josephson IR. Lidocaine blocks Na, Ca, and K currents of chick ventricular myocytes. J Mol Cell Cardiol. 1988;20:593–604.
23. Tanaka Y, Kamibayashi M, Yamashita Y, Imai T, Tanaka H, Nakahara T, Ishii K, Shigenobu K. Evidence for the possible involvement of Ca2+ entry blockade in the relaxation by class I antiarrhythmic drugs in the isolated pig coronary smooth muscle. Naunyn Schmiedebergs Arch Pharmacol. 2002;365(1):56–66.
24. Toda N, Toda H, Hatano Y. Nitric oxide: involvement in the effects of anesthetic agents. Anesthesiology. 2007;105(5):822–42.
25. Newton DJ, McLeod GA, Khan F, Belch JJ. Mechanisms influencing the vasoactive effects of lidocaine in human skin. Anaesthesia. 2007;62(2):146–50.
26. Takaishi K, Kitahata H, Kawahito S. Local anesthetics inhibit nitric oxide production and L-arginine uptake in cultured bovine aortic endothelial cells. Eur J Pharmacol. 2013;704(1-3):58–63.
27. Scholz A. Mechanisms of (local) anaesthetics on voltage-gated sodium and other ion channels. Br J Anaesth. 2002;89(1):52–61.
28. Hollmann MW, Wieczorek KS, Berger A, Durieux ME. Local anesthetic inhibition of G protein-coupled receptor signaling by interference with Galpha(q) protein function. Mol Pharmacol. 2001;59(2):294–301.
29. Benkwitz C, Garrison JC, Linden J, Durieux ME, Hollmann MW. Lidocaine enhances Galphai protein function. Anesthesiology. 2003;99(5):1093–101.
30. Peart JN, Headrick JP. Adenosinergic cardioprotection: multiple receptors, multiple pathways. Pharmacol Ther. 2007;114(2):208–21.
31. Dogan M, Peker RO, Donmez S, Gokalp O. Magnesium and diltiazem relaxes phenylephrine-precontracted rat aortic rings. Interact Cardiovasc Thorac Surg. 2012;15(1):1–4.
32. Zerkowski HR, Knocks M, Konerding MA, Doetsch N, Roth G, Hakim K, Reidemeister JC. Endothelial damage of the venous graft in CABG. Influence of solutions used for storage and rinsing on endothelial function. Eur J Cardiothorac Surg. 1993;7(7):376–82.
33. Furchgott RF. Role of endothelium in responses of vascular smooth muscle. Circ Res. 1983;53:557–73.
34. Rautureau Y, Toumaniantz G, Serpillon S, Jourdon P, Trochu J-T, Guathier C. Beta 3-adrenoceptor in rat aorta: molecular and biochemical characterization and signalling pathway. Br J Pharmacol. 2002;137:153–61.
35. Novakovic A, Bukarica LG, Kanjuh V, Heinle H. Potassium channels-mediated vasorelaxation of rat aorta induced by resveratrol. Basic Clin Pharmacol Toxicol. 2006;99:360–4.

36. Mackie MR, Byron KL. Cardiovascular KCNQ (Kv7) potassium channels: physiological regulators and new targets for therapeutic intervention. Mol Pharmacol. 2008;74(5):1171–9.

37. O'Rourke B. Mitochondrial K$_{ATP}$ channels in preconditioning. Circ Res. 2000; 87:845–55.

38. Toyoda Y, Friehs I, Parker RA, Levitsky S, McCully JD. Differential role of sarcolemmal and mitochondrial K(ATP) channels in adenosine-enhanced ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2000;279(6): H2694–703.

39. Gross ER, Gross GJ. Pharmacologic therapeutics for cardiac reperfusion injury. Expert Opin Emerg Drugs. 2007;12(3):367–88.

40. Grbovic L, Radenkovic M. Analysis of adenosine vascular effect in isolated rat aorta: possible role of Na+/K + -ATPase. Pharmacol Toxicol. 2003;92(6):265–71.

41. Anastacio MM, Kanter EM, Makepeace CM, Keith AD, Zhang H, Schuessler RB, Nichols CG, Lawton JS. Relationship between mitochondrial matrix volume and cellular volume in response to stress and the role of ATP-sensitive potassium channel. Circulation. 2013;128(11 Suppl 1):S130–5.

42. Hanley PJ, Gopalan KV, Lareau RA, Srivastava DK, von Meltzer M, Daut J. Beta-oxidation of 5-hydroxydecanoate, a putative blocker of mitochondrial ATP-sensitive potassium channels. J Physiol. 2003;547(Pt 2):387–93.

43. Li X, Rapedius M, Baukrowitz T, Liu GX, Srivastava DK, Daut J, Hanley PJ. 5-Hydroxydecanoate and coenzyme A are inhibitors of native sarcolemmal KATP channels in inside-out patches. Biochim Biophys Acta. 2010;1800(3):385–91.

44. Jacobson KA, Nikodijević O, Padgett WL, Gallo-Rodriguez C, Maillard M, Daly JW. 8-(3-Chlorostyryl)caffeine (CSC) is a selective A2-adenosine antagonist in vitro and in vivo. FEBS Lett. 1993;323(1-2):141–4.

45. Mathoôt RA, Soudijn W, Breimer DD, Ijzerman AP, Danhof M. Pharmacokinetic-haemodynamic relationships of 2-chloroadenosine at adenosine A1 and A2a receptors in vivo. Br J Pharmacol. 1996;118(2):369–77.

46. Allende G, Acevedo S. Evidence for a role of cyclic AMP and endothelium in rat aortic relaxation induced by R-PIA. Open Circ Vasc J. 2011;4:6–11.

47. Borrmann T, Hinz S, Bertarelli DCG, Li W, Florin NC, Scheiff AB, Müller CE. 1-Alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. J Med Chem. 2009;52(13):3994–4006.

48. Van der Walt MM, Terre'Blanche G, Petzer A, Lourens ACU, Petzer JP. The adenosine A2A antagonistic properties of selected C8-substituted xanthines. Bioorg Chem. 2013;49:49–58.

49. Grbović L, Radenković M, Prostran M, Pešić S. Characterization of adenosine action in isolated rat renal artery. Possible role of adenosine A(2A) receptors. Gen Pharmacol. 2000;35(1):29–36.

50. Perlmutter NS, Wilson RA, Edgar SW, Sanders W, Greenberg BH, Tanz R. Vasodilatory effects of lidocaine on epicardial porcine coronary arteries. Pharmacology. 1990;41(5):280–5.

51. Jembeck J, Samuelson UE. Effects of lidocaine and calcitonin gene-related peptide (CGRP) on isolated human radial arteries. J Reconstr Microsurg. 1993;9(5):361–5.

52. Gherardini G, Samuelson U, Jernbeck J, Aberg B, Sjöstrand N. Comparison of vascular effects of ropivacaine and lidocaine on isolated rings of human arteries. Acta Anaesthesiol Scand. 1995;39(6):765–8.

53. Gherardini G, Evans GR, Milner SM, Gurlek A, Palmer B, Gazelius B, Lundeberg T. Comparison of vascular effects of calcitonin gene-related peptide and lidocaine on human veins. J Reconstr Microsurg. 1996;12(4):241–5.

54. Dobson GP. Addressing the global burden of trauma in major surgery. Front Surg. 2015;2(Sept):43. doi:10.3389/fsurg.2015.00043.

55. Tsai M-H, Jiang MJ. Reactive oxygen species are involved in regulating α1-adrenoceptor-activated vascular smooth muscle contraction. J Biomed Sci. 2010;17(Aug 23):67.

56. Hsieh H-J, Liu C-A, Huang B, Tseng AHH, Wang DL. Shear-induced endothelial mechanotransduction: the interplay between reactive oxygen species (ROS) and nitric oxide (NO) and the pathophysiological implications. J Biomed Sci. 2014;21(Jan 13):3.

57. Rogers PA, Chilian WM, Bratz IN, Bryan RMJ, Dick GM. H2O2 activates redox- and 4-aminopyridine-sensitive Kv channels in coronary vascular smooth muscle. Am J Physiol Heart Circ Physiol. 2007;292(3):H1404–11.

58. Amberg GC, Navedo MF. Calcium dynamics in vascular smooth muscle. Microcirculation. 2013;20(4):281–9.

59. Webb RC. Smooth muscle contraction and relaxation. Adv Physiol Educ. 2003;27(1-4):201–6.

60. Kemp BK, Cocks TM. Adenosine mediates relaxation of human small resistance-like coronary arteries via A2B receptors. Br J Pharmacol. 1999; 126(8):1796–800.

61. Hein TW, Xu W, Ren Y, Kuo L. Cellular signalling pathways mediating dilation of porcine pial arterioles to adenosine A2A receptor activation. Cardiovasc Res. 2013;99(1):156–63.

62. Linden J. Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Ann Rev Pharmacol Toxicol. 2001;41:775–87.

63. Stella SLJ, Bryson EJ, Thoreson WB. A2 adenosine receptors inhibit calcium influx through L-type calcium channels in rod photoreceptors of the salamander retina. J Neurophysiol. 2002;87(1):351–60.

64. Gubitz AK, Widdowson L, Kurokawa M, Kirkpatrick KA, Richardson PJ. Dual signalling by the adenosine A2a receptor involves activation of both N- and P-type calcium channels by different G proteins and protein kinases in the same nerve terminals. J Neurochem. 1996;67:374–81.

65. Goncalves ML, Cunha RA, Ribeiro JA. Adenosine A2A receptors facilitate 45Ca2+ uptake through class A calcium channels in rat hippocampal CA3 but not CA1 synaptosomes. Neurosci Lett. 1997;238:73–7.

66. Lawson DL, Mehta JL, Mehta P, Nichols WW. Endothelium-dependent relaxation of rat aortic rings by leukotriene D4: importance of the magnitude of preload. Eicosanoids. 1989;2(3):175–81.

67. Bellien J, Favre J, Iacob M, Gao J, Thuillez C, Richard V, Joannidès R. Arterial stiffness is regulated by nitric oxide and endothelium-derived hyperpolarizing factor during changes in blood flow in humans. Hypertension. 2010;55(3):674–80.

68. Marti CN, Gheorghiade M, Kalogeropoulos AP, Georgiopoulou VV, Quyyumi AA, Butler J. Endothelial dysfunction, arterial stiffness, and heart failure. J Am Coll Cardiol. 2012;60(16):1455–69.

69. Gur O, Ege T, Gurkan S, Ozkaramanli GD, Karadag H, Cakir H, Duran E. In vitro effects of lidocaine hydrochloride on coronary artery bypass grafts. J Cardiovasc Surg (Torino). 2012;53(5):665–9.

70. Li QY, Xu WL, Zhang Y, Lu PS, Yuan ZC, Zhan LP, Wang P, Lu XY, Cheng B. Intravascular infusion of lidocaine: a novel way to relieve sudden internal carotid artery occlusion in embolization of intracranial aneurysms. J Neurol Surg A Cent Eur Neurosurg. 2012;73(2):84–8.

71. Zeiler FA, Sader N, Kazina CJ. The impact of intravenous lidocaine on ICP in neurological illness: a systematic review. Crit Care Res Pract. 2015;2015:485802.

72. Baraka A, Hirt N, Dabbous A, Taha S, Rouhana C, Khoury N, Ghabash M, Jamhoury M, Sibaii A. Lidocaine cardioplegia for prevention of reperfusion ventricular fibrillation. Ann Thorac Surg. 1993;55:1529–33.

73. Dobson GP, Faggian G, Onorati F, Vinten-Johansen J. Hyperkalemic cardioplegia in adult and pediatric cardiac surgery: end of an Era? Front Clin Transl Physiol. 2013;4(Aug 28):1–28.